OnKure Therapeutics (OKUR) grants 300,000 options and reprices 15,300 for director

Rhea-AI Filing Summary

OnKure Therapeutics director Isaac Manke reported equity compensation and option repricing activity involving stock options for Class A Common Stock. On August 7, 2026 he received a grant of 300,000 stock options with an exercise price of $4.14 per share, expiring on August 6, 2036. One quarter of these options vests on February 24, 2027 and the remainder vests in equal monthly installments over the following 36 months, contingent on continued service. On the same date, 15,300 options with an original exercise price of $18.20 per share expiring October 3, 2034 were returned to the issuer and replaced with 15,300 repriced options at an exercise price of $4.14, with the same vesting and expiration. Under the company’s one-time Option Repricing program, if any repriced option is exercised before the end of a defined retention period, the holder must pay the original higher exercise price instead of $4.14.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Manke Isaac

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	300,000	$0.00	$0.00
Disposition	Stock Option (right to buy) F3, F4, F2	15,300	--	--
Grant/Award	Stock Option (right to buy) F3, F4, F2	15,300	--	--

Holdings After Transaction: Stock Option (right to buy) — 315,300 shares (Direct)

Footnotes (4)

1. F1. 1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
2. F2. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.
3. F3. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.
4. F4. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

Key Figures

New option grant: 300,000 stock options Repriced options: 15,300 stock options Repriced exercise price: $4.14 per share +3 more

6 metrics

New option grant 300,000 stock options Granted to Isaac Manke on August 7, 2026

Repriced options 15,300 stock options Returned to issuer and regranted on August 7, 2026

Repriced exercise price $4.14 per share Exercise price for new and repriced options, set at closing price on Effective Date

Original exercise price $18.20 per share Original exercise price of the 15,300 options repriced on August 7, 2026

New grant expiration August 6, 2036 Expiration date of 300,000-option grant

Repriced options expiration October 3, 2034 Expiration date for the 15,300 repriced options

Key Terms

Option Repricing, Retention Period, Change in Control, Class A Common Stock

4 terms

Option Repricing financial

"The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing")"

Retention Period financial

"before the end of a "Retention Period" through which the option holder must remain in service"

Change in Control financial

"ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control"

A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.

Class A Common Stock financial

"the closing price of the Issuer's Class A Common Stock on the Effective Date"

Class A common stock is a category of a company’s shares that carries a specific set of ownership rights—most commonly defined voting power and claims on dividends—set out in the company’s charter. For investors it matters because the class determines how much influence you have over corporate decisions, the share’s likely dividend and trading behavior, and how it compares in value to other share classes, like choosing a particular seat with different privileges at the company’s decision-making table.

FAQ

What stock option grant did OnKure Therapeutics (OKUR) director Isaac Manke receive?

Isaac Manke received a grant of 300,000 stock options on August 7, 2026 with an exercise price of $4.14 per share, expiring on August 6, 2036, subject to time-based vesting tied to continued service.

How do the 300,000 new options for OKUR vest for Isaac Manke?

For the 300,000 options, 1/4 vests on February 24, 2027, and 1/48 vests monthly thereafter until fully vested, provided Manke continues as a service provider through each vesting date.

What options were repriced for Isaac Manke at OnKure Therapeutics (OKUR)?

Manke had 15,300 stock options originally priced at $18.20 per share, expiring October 3, 2034, returned to the issuer and replaced with 15,300 options repriced to $4.14 per share, with vesting schedule and expiration unchanged.

What is the new exercise price after the OKUR option repricing for Manke?

Under the Option Repricing effective August 7, 2026, the affected options, including Manke’s, now have an exercise price of $4.14 per share, equal to the closing price of OnKure’s Class A Common Stock on that date.

What is the retention period condition on OnKure Therapeutics (OKUR) repriced options?

If a repriced option is exercised before the end of the Retention Period, the holder must pay a premium exercise price equal to the option’s original exercise price; after this period, the $4.14 repriced level applies.

Did the OKUR option repricing change the number of shares or vesting terms?

For the repriced awards, there was no change to the vesting schedules, expiration dates or number of shares underlying the options; only the exercise price mechanics were amended under the Option Repricing program.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/11/2026 - 04:39 PM Accepted by SEC EDGAR 08/11/2026 - 04:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Manke Isaac

(Last) (First) (Middle)

C/O ONKURE THERAPEUTICS, INC.

6707 WINCHESTER CIRCLE, SUITE 400

(Street)

BOULDER COLORADO 80301

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OnKure Therapeutics, Inc. [ OKUR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/07/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.14	08/07/2026		A		300,000		(1)	08/06/2036	Class A Common Stock	300,000	$0	300,000	D
Stock Option (right to buy)	$18.2	08/07/2026		D			15,300	(2)	10/03/2034	Class A Common Stock	15,300	(3)(4)	0	D
Stock Option (right to buy)	$4.14	08/07/2026		A		15,300		(2)	10/03/2034	Class A Common Stock	15,300	(3)(4)	15,300	D

Explanation of Responses:

1. 1/4th of the shares subject to the option shall vest on February 24, 2027 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

2. 1/36th of the shares subject to the option vested on November 4, 2024 and 1/36th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

3. The transactions reported herein reflect a one-time stock option repricing (the "Option Repricing") effective on August 7, 2026 (the "Effective Date"). The Option Repricing applies to options with exercise prices equal to or greater than $10.00 per share held by all continuing employees and certain other service providers of the Issuer as of the Effective Date.

4. Pursuant to the Option Repricing, the exercise price of the repriced options, including the reported option, has been amended to reduce the exercise price to $4.14 per share, the closing price of the Issuer's Class A Common Stock on the Effective Date. However, if an option holder exercises a repriced option before the end of a "Retention Period" through which the option holder must remain in service to the Issuer, then the option holder will be required to pay a premium exercise price that is equal to the original exercise price per share of such option. The "Retention Period" begins on the Effective Date of the Option Repricing and ends on the earliest to occur of the following: (i) February 7, 2028 or (ii) a Change in Control, as defined in the Issuer's 2021 Stock Incentive Plan or 2024 Equity Incentive Plan (as applicable). There was no change to the vesting schedules, expiration dates or number of shares underlying the repriced options.

	/s/ Rogan Nunn, by power of attorney	08/11/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)